Ziconotide

Ziconotide provides analgesia for severe chronic pain through selective blockade of N-type voltage-gated calcium channels in the spinal cord, inhibiting release of pro-nociceptive neurotransmitters such as glutamate, substance P, and CGRP.¹,²,³ It is indicated for intrathecal management of severe chronic pain in patients refractory to or intolerant of other treatments, including systemic analgesics, adjunctive therapies, or intrathecal morphine, with evidence from pivotal double-blind trials supporting its efficacy in neuropathic and nociceptive pain.¹,²,⁴ Preclinical models demonstrate potent antihyperalgesic and antiallodynic effects in inflammatory and neuropathic pain, outperforming morphine in persistent and chronic pain states, though human mechanisms remain partly unconfirmed.² Clinical use involves continuous intrathecal infusion via implanted pumps, starting at low doses like 0.1 μg/h and titrated up to 0.8 μg/h.³ Regulatory assessments note moderate clinical benefit but no added value over opioids in some pathways.⁵

Ziconotide commonly causes dizziness, nausea, diarrhea, weakness, somnolence, vomiting, confusion, gait instability, ataxia, headache, blurred vision, and nystagmus, with many adverse events being mild to moderate but potentially leading to treatment discontinuation if titration is not slowed.⁶,⁷ Serious safety concerns include risk of meningitis (with symptoms like fever, stiff neck, headache, and seizures), severe psychiatric symptoms such as hallucinations or depression, neurological impairment, presyncopal episodes, elevated creatine kinase levels requiring monthly monitoring, and overdose symptoms like decreased responsiveness or severe sleepiness.³,⁶,⁷,⁸ Other notable effects encompass urinary retention, memory impairment, dysarthria, tremor, and catheter site reactions, often managed by dose adjustment or supportive care.⁴,⁷,⁹ Intrathecal administration via infusion pump demands careful titration to minimize neuropsychiatric and cognitive risks, with no observed tolerance development.³,⁷ Patients should report any signs of infection, mood changes, or muscle weakness promptly.⁴,⁶

Ziconotide selectively binds to and blocks N-type voltage-gated calcium channels (Cav2.2) on presynaptic terminals of primary nociceptive A-δ and C-afferent fibers in the superficial layers (Rexed laminae I and II) of the spinal cord dorsal horn.⁷,⁸,¹⁰,¹¹ This blockade prevents calcium influx necessary for synaptic vesicle fusion, thereby inhibiting the release of excitatory neurotransmitters such as glutamate, substance P, and calcitonin gene-related peptide (CGRP) from these afferents.⁷,¹⁰,¹² The reduction in neurotransmitter release diminishes excitation of second-order neurons in the spinal cord, interrupting pain signal transmission to the brain without interacting with opioid receptors.²,⁷,¹⁰ Its specificity for N-type channels, achieved through direct occlusion of the channel pore, minimizes effects on other calcium channel types.²,¹¹ Administered intrathecally, ziconotide diffuses directly to these sites in the cerebrospinal fluid for targeted action.⁸,¹⁰